At A Forum for Improving Drug Safety, a recent blog post excerpts an email sent by Genelex CEO Howard Coleman to people interested in promoting warfarin testing. The Center for Medicare and Medicaid Services has begun a study on whether the test should be covered by insurance and is accepting public comment until tomorrow. "I believe that adherence to unreasonably difficult standards of proof for pharmacogenetic tests has resulted in harm to many, many patients," Coleman writes, directing readers to an article in GTO's sister publication, Pharmacogenomics Reporter, for background.
Speak Up for Insuring Warfarin Testing
Sep 02, 2008